Brain – Start
The Brain Start stack pairs three widely studied neuropeptides — Semax, Selank and P21 — into one curated kit for cognitive and neuroplasticity research. It supports work on attention, stress modulation and BDNF-linked signalling.
Each peptide is supplied at research-grade purity for laboratory use. For research purposes only; not for human consumption.
Original price was: 209,00 €.178,00 €Текущата цена е: 178,00 €.
Ноотропен изследователски комплект, комбиниращ Semax, Selank и P21 за проучвания върху познанието, фокуса и невропластичността.
Временно не е налично. Оставете данните си и ще ви уведомим веднага щом се появи.
Brain - Start - Foundational Cognitive Research Stack
Explored with Semax
Investigated with Semax
Studied with Selank
Focus of P21 (P021) research
Explored with P21 (P021)
Potential with Selank
Research with Semax
Key area for Selank
Description
Mechanism of Action
Semax, a synthetic peptide, is researched for its neuroprotective and nootropic properties, potentially modulating BDNF and neurotransmitter activity. Selank, an anxiolytic peptide, is studied for its impact on stress response and immune function, complementing cognitive research. P21 (P021), a neurotrophic factor mimic, is explored for promoting neurogenesis, synaptic plasticity, and neuronal survival, offering a multi-faceted approach to brain health research.
Benefits
- Cognitive Enhancement – Investigated with Semax for focus and memory.
- Stress Modulation – Explored with Selank for anxiolytic effects.
- Neuroprotection Research – Supported by Semax and P21’s potential.
- Synaptic Plasticity – A key area of study for P21 (P021).
- Mood Regulation – Potential research focus with Selank.
- Neuronal Growth – P21 (P021) is studied for its role in neurogenesis.
Research Data
Semax
| Study / Model | Reported effect |
|---|---|
| Ischemic stroke patients (clinical study) | Improved neurological recovery and reduced infarct progression when administered within acute window |
| Rat middle cerebral artery occlusion model | ↓ Infarct volume; ↑ neuronal survival in penumbra region |
| Rat hippocampal tissue assay | ↑ BDNF and NGF expression within hours of administration |
| Healthy human cognitive trials | ↑ Attention, memory consolidation, and operator performance under fatigue |
| Chronic stress rodent model | Reduced anxiety-related behaviors; normalized HPA-axis activity |
| In vitro neuronal culture | Enhanced dopaminergic and serotonergic signaling; protection against oxidative injury |
| Optic nerve atrophy model | ↑ Retinal ganglion cell survival and improved visual response markers |
Selank
| Study / Model | Reported effect |
|---|---|
| Generalized anxiety disorder clinical trials | ↓ anxiety scores comparable to medazepam without sedation or withdrawal |
| Rat elevated plus-maze model | ↓ anxiety-like behavior; ↑ open-arm exploration time |
| Cortical neurotransmitter analysis (rodent) | Normalized GABA turnover; ↑ serotonin and dopamine metabolism |
| BDNF expression studies in hippocampus | ↑ BDNF mRNA expression supporting neuroplasticity |
| Stress-induced immunosuppression models | Restored interferon and cytokine balance; ↑ immune resilience |
| Cognitive performance tasks in healthy volunteers | ↑ attention, memory consolidation, and mental endurance |
| Enkephalin degradation assays | Inhibition of enkephalin breakdown; prolonged endogenous opioid activity |
P21 (P021)
| Study / Model | Reported effect |
|---|---|
| Aged rat hippocampus | ↑ BDNF expression, ↑ neurogenesis, improved spatial memory performance |
| 3xTg-AD Alzheimer’s mouse model | ↓ tau hyperphosphorylation, ↓ amyloid-β pathology, preserved cognitive function |
| Down syndrome mouse model (Ts65Dn) | Restored dentate gyrus neurogenesis and rescued learning deficits |
| Streptozotocin-induced cognitive impairment (rats) | ↑ synaptic plasticity markers, ↓ neuroinflammation, improved memory retention |
| In vitro neuronal cultures | ↑ CREB phosphorylation and BDNF/TrkB signaling activity |
| Traumatic brain injury rodent model | ↓ neuronal loss, ↑ dendritic spine density in hippocampal regions |
Stack Suggestions
This research bundle is designed for investigators exploring foundational cognitive support, stress response modulation, and neurotrophic pathways. It offers a synergistic approach to understanding brain health and resilience in research models.
Pen Dosage Chart
Semax
| Semax Pen 30 mg | |
|---|---|
| Volume | 3.0 mL (after reconstitution) |
| mg/mL | 10 mg/mL |
| Click-to-Dose | 1 click = 0.1 mg |
| Example(s) | 3 clicks = 0.3 mg; 6 clicks = 0.6 mg |
Selank
| Selank Pen 10 mg | |
|---|---|
| Volume | 2.0 mL (after reconstitution) |
| mg/mL | 5.0 mg/mL |
| Click-to-Dose | 1 click = 0.05 mg |
| Example(s) | 30 clicks = 1.5 mg; 60 clicks = 3 mg |
P21 (P021)
| P21 Pen 10 mg | |
| Volume | 2 mL |
| mg/mL | 5 mg/mL |
| Click-to-Dose | 1 click = 0.05 mg |
| Example(s) | 10 clicks = 0.5 mg |
Dosage & Protocols Variations
Semax
Standard Research Protocol
- Dose: 0.3 – 0.6 mg (= 3–6 clicks)
- Duration: 2 – 4 weeks
- Frequency: Daily
- Cycle Interval: 2 – 4 weeks off before repeating
- Goal / Description: Baseline cognitive and neurotrophic research applications.
Therapeutic Research Protocol
- Dose: 0.6 – 1.2 mg (= 6–12 clicks)
- Duration: 1 – 2 weeks
- Frequency: Daily, divided into 2 – 3 doses
- Cycle Interval: 3 – 4 weeks off before repeating
- Goal / Description: Higher-dose protocol used in stroke recovery and neuroprotection models.
Biohacker Protocol (experimental)
- Dose: 0.1 – 0.3 mg (= 1–3 clicks)
- Duration: 4 – 6 weeks
- Frequency: Daily, morning administration
- Cycle Interval: 2 weeks off before repeating
- Goal / Description: Low-dose continuous exposure for cognitive and focus research.
Selank
Standard Research Protocol
- Dose: 0.25 – 0.5 mg (= 5–10 clicks)
- Duration: 2 – 3 weeks
- Frequency: Daily (SubQ)
- Cycle Interval: 2 – 4 weeks off before repeating
- Goal / Description: Baseline protocol for anxiolytic and cognitive stability models.
Therapeutic Research Protocol
- Dose: 0.5 – 0.9 mg (= 10–18 clicks)
- Duration: 3 – 4 weeks
- Frequency: 2× daily, divided doses
- Cycle Interval: 4 weeks off before repeating
- Goal / Description: Higher-dose protocol used in stress-response and GABAergic modulation studies.
Biohacker Protocol (experimental)
- Dose: 0.1 – 0.2 mg (= 2–4 clicks)
- Duration: 4 – 6 weeks
- Frequency: Daily microdose
- Cycle Interval: 2 weeks off before repeating
- Goal / Description: Low-dose continuous exposure for cognitive and mood-balance research.
Stacked Protocol (Selank + Semax)
- Dose: 0.3 mg Selank + 0.3 mg Semax (= 6 clicks)
- Duration: 2 – 3 weeks
- Frequency: Daily
- Cycle Interval: 3 – 4 weeks off before repeating
- Goal / Description: Combined neuropeptide protocol for cognitive and anxiolytic research models.
P21 (P021)
Standard Research Protocol
- Dose: 0.5 – 1.0 mg
- Duration: 4 – 8 weeks
- Frequency: Daily, oral or intranasal
- Cycle Interval: 2 – 4 weeks off before repeating
- Goal / Description: Baseline cognitive and neurotrophic research applications.
Neuroprotective Research Protocol
- Dose: 1.0 – 2.0 mg
- Duration: 8 – 12 weeks
- Frequency: Daily
- Cycle Interval: 4 weeks off before repeating
- Goal / Description: Extended-duration models targeting BDNF upregulation and neurogenesis.
Biohacker Protocol (experimental)
- Dose: 0.25 – 0.5 mg
- Duration: Continuous
- Frequency: 5 days on, 2 days off
- Cycle Interval: Continuous with weekly pause
- Goal / Description: Low-dose continuous exposure for long-term cognitive research models.
Possible Side Effects
Semax
Semax is generally well-tolerated in clinical and preclinical research, including intranasal and subcutaneous administration studies.
Reported side effects are infrequent and typically mild:
- Mild nasal irritation or transient burning sensation with intranasal use.
- Headache or lightheadedness during initial dosing.
- Temporary changes in alertness or sleep patterns.
- Mild fatigue or restlessness in sensitive subjects.
- Localized redness at subcutaneous injection sites.
No evidence of hormonal, cardiovascular, or systemic adverse effects has been observed in available research data. Long-term safety beyond standard study durations remains under investigation in experimental models.
Selank
Selank is generally well-tolerated in animal and limited human clinical studies, with no significant adverse effects reported at standard research doses.
Reported observations include:
- Mild transient drowsiness or fatigue during initial dosing.
- Occasional headache or lightheadedness in sensitive subjects.
- Localized irritation or redness at the injection site.
- Rare reports of mild nasal discomfort with intranasal administration.
Unlike classical anxiolytics, Selank has not been observed to produce sedation, dependence, withdrawal, or cognitive impairment in available research data. No evidence of hormonal, hepatic, or cardiovascular adverse effects has been documented.
P21 (P021)
P21 is generally well-tolerated in preclinical and animal studies.
Reported side effects are rare and mild:
- Mild transient fatigue or drowsiness during initial dosing periods.
- Localized irritation or redness at injection site.
- Occasional headache or lightheadedness reported in sensitive subjects.
- Subtle mood fluctuations during early adaptation phase.
No evidence of neurotoxic, hepatic, or systemic adverse effects has been observed in available research data.
Product Attributes
Scientific References
Semax
- Semax, an analogue of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus Animal | In vitro
- Semax, an analog of ACTH(4-7), regulates expression of immune response genes during ischemic brain injury in rats Animal
- Heptapeptide Semax Effects on Expression of Genes Related to Neurotransmitter Systems Animal | In vitro
- Heptapeptide semax attenuates the effects of chronic unpredictable stress in rats Animal
- The nootropic and analgesic effects of Semax following different routes of administration Animal
- Effect of Semax and its C-terminal fragment PGP on the in vivo dopamine release in the nucleus accumbens of rats Animal
- Semax, an analog of ACTH(4-7), regulates expression of immune response genes in ischemic rat brain Animal
- Semax: research overview, mechanisms, and effects Observational | Animal
Selank
- Anxiolytic activity of the heptapeptide Selank in clinical trials Human RCT | Observational
- Effects of Selank on the expression of genes encoding inflammatory factors and BDNF Animal | In vitro
- Selank enhances the expression of BDNF and the trkB receptor in the hippocampus Animal
- Comparative study of the anxiolytic effects of Selank and medazepam in patients with generalized anxiety disorder Human RCT
- Effect of Selank on monoamine neurotransmitter metabolism in the brain of rats Animal
- Selank and its analogs modulate GABAergic transmission in experimental anxiety models Animal | In vitro
- Peptide Selank as a candidate for the correction of cognitive deficits Animal
- Immunomodulatory and anxiolytic properties of the synthetic peptide Selank Observational | Animal
P21 (P021)
- Neurogenic and neurotrophic effects of BDNF peptides in mouse hippocampal primary neuronal cell cultures Animal | In vitro
- A small molecule peptide inhibitor of amyloid plaque, oxidative stress, and neuronal loss Animal | In vitro
- Ciliary neurotrophic factor derived peptide P021 ameliorates plaque pathology and improves cognition in Alzheimer disease mouse model Animal
- Neurotrophic peptide P021 rescues hippocampal neurogenesis and synaptic plasticity in a tauopathy mouse model Animal | In vitro
- P021 rescues tau pathology and behavioral deficits in a mouse model of tauopathy by inhibiting GSK-3β Animal
- Neurotrophic compound P021 reduces neuroinflammation and enhances cognitive function in aged rats Animal
- Peptidomimetic P021 promotes neurogenesis and reduces glycogen synthase kinase-3 activity in Down syndrome models Animal | In vitro
- CNTF-derived peptide rescues synaptic and cognitive deficits in a 3xTg-AD model Animal
Включено в кутията
Всеки продукт пристига в премиум, специално проектирана кутия на PEPTIDE.Power, проектирана за удобство, хигиена и безопасно съхранение във вашия хладилник. Вътре ще намерите всичко необходимо за пълния ви изследователски протокол:
- 1× Еднократна предварително смесена инжекционна писалка
- Захранван от нашата патентована PSM Technology™ – прецизна система за стабилизация & смесване за постоянна ефикасност
- 10× Ултратънки игли (33G, 4 мм)
- 10× Спиртни тампони за стерилна подготовка
- Вътрешна стабилизираща дунапренова вложка за предотвратяване на разклащане по време на транспорт
- Панел с инструкции, отпечатан от вътрешната страна на кутията за бърза справка
- Стикер за защитен печат, гарантиращ, че опаковката не е отваряна или манипулирана
Съхранение
Съхранявайте продукта в хладилник при 1 – 7°C веднага след доставка. За да поддържате оптимална стабилност, дръжте писалката далеч от светлина и не я излагайте на повтарящи се температурни промени.
След като бъдат реконституирани (всички наши писалки са предварително смесени), изследователските съединения остават стабилни за 6 – 8 седмици при правилно съхранение в хладилник.
Не замразявайте след реконституция. Винаги дръжте кутията затворена, така че писалката, иглите и спиртните тампони да останат чисти и защитени.
За най-добри резултати използвайте продукта последователно в рамките на препоръчителния времеви прозорец и винаги следвайте вашия изследователски протокол.
Доставка
Изпращаме с Доставка в ЕС на следващия ден чрез DHL Express или UPS Express.
Всички поръчки се приготвят свежи в деня на изпращане, поставят се в EPS транспортни кутии за студена верига и се изпращат с охлаждащи елементи за поддържане на стабилна температура по време на целия път.
Нашият логистичен процес е проектиран така, че пратката да пристигне за една нощ, избягвайки митнически забавяния в рамките на Европейския съюз.
Продуктите се изпращат от нашето съоръжение в ЕС, осигурявайки без вносни мита, без митническо освобождаване и винаги бърза и сигурна доставка.
Плащане
Поради естеството на изследователските пептиди и категорията с висок риск, определена от платежните оператори, компаниите за кредитни карти не поддържат търговци в тази област.
Поради тази причина приемаме само банкови преводи.
В рамките на Европейския съюз, SEPA преводите са бързи, нискотарифни и обикновено пристигат в рамките на минути до няколко часа, което прави процеса на плащане гладък и прост.
След като преводът бъде получен, вашата поръчка се подготвя незабавно и се изпраща същия ден (в зависимост от часа на поръчка).
Този метод осигурява съответствие, сигурност и непрекъснатост на услугата за всички клиенти в целия ЕС.
Не намерихте отговор на въпроса си?
Вижте всички често задавани въпросиRELATED PRODUCTS
